Cyclophosphamide and glucocorticoids are the mainstay of induction therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; however, this treatment is associated with high mortality and serious adverse events. New results indicate that rituximab, an anti-CD20 monoclonal antibody, has similar safety and efficacy to cyclophosphamide in this setting, at least in the short term.
In a multicenter, double-blind, double-dummy, noninferiority trial, Stone et al. randomly assigned patients with severe, newly diagnosed or relapsing disease to receive standard glucocorticoid therapy plus either rituximab (n = 99) or cyclophosphamide (n = 98). Adverse event rates did not differ between these groups, and similar proportions of patients achieved steroid-free remission at 6 months. However, the rituximab-based regimen more effectively induced remission in patients with relapsing disease; 34 of 51 such patients treated with rituximab achieved steroid-free remission, compared with 21 of 50 those treated with cyclophosphamide.
Jones and colleagues report similar and complementary findings in an open-label, parallel-design, randomized trial. Patients with newly diagnosed, severe disease received either rituximab with two doses of cyclophosphamide and glucocorticoids (n = 33) or cyclophosphamide and glucocorticoids (n = 11). Rates of severe adverse events and sustained remission were similar at 12 months in both groups.
Rituximab-based therapy did not improve either the safety or efficacy of induction treatment for ANCA-associated vasculitis in the two studies. Nonetheless, the researchers remain optimistic about the potential long-term benefits, most likely to be related to a decreased need for maintenance immunosuppression and reduced cumulative exposure to cyclophosphamide. Stone et al. and Jones et al. thus plan to monitor their patients for ≥18 months and ≥24 months, respectively. Rituximab could be a valuable option for patients at the greatest risk of cyclophosphamide-related adverse effects and might even become the first choice for the treatment of relapsing disease.
ORIGINAL RESEARCH PAPERS
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010)
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010)
Rights and permissions
About this article
Cite this article
Nanda, S. Rituximab has similar short-term safety and efficacy to cyclophosphamide in ANCA-associated vasculitis. Nat Rev Rheumatol 6, 556 (2010). https://doi.org/10.1038/nrrheum.2010.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.150